NORTHWEST BIOTHERAPEUTICS INC Annual Report - How They Did This Year

I’ve put together this guide to help you understand Northwest Biotherapeutics (NWBO) based on their latest filings. Think of this as a plain-English breakdown of where the company stands, what they’ve been doing, and what you should watch as an investor.

1. What does this company do?

Northwest Biotherapeutics is a biotech company developing personalized immune therapies for solid tumors. Their lead platform, DCVax-L, trains a patient’s own immune system to fight glioblastoma (a type of brain cancer). Their second platform, DCVax-Direct, treats inoperable tumors by injecting the vaccine directly into the site. As of the 2025 fiscal year-end, the company is in the pre-revenue stage as both platforms remain in the testing and regulatory phase.

2. Major wins this year

• Regulatory Progress: The company completed a major Phase III trial with 331 patients across four countries. Results published in JAMA Oncology showed that patients lived longer using DCVax-L compared to standard care. They have submitted their data to the U.K.’s health regulator (MHRA) to seek approval for commercial use.
• Intellectual Property: The company holds 58 issued patents worldwide, with 3 new patents secured this year. This portfolio provides a layer of protection for their technology through the 2035–2040 timeframe.
• Orphan Drug Status: DCVax-L holds "Orphan Drug" status in the U.S. and E.U. This designation provides specific benefits, including tax incentives, reduced regulatory fees, and periods of market exclusivity that help protect the product from immediate competition upon approval.

3. Financial health

The company is currently operating at a loss, which is typical for a biotech firm in the clinical development stage. For the year ending December 31, 2025, expenditures totaled approximately $45 million, primarily driven by research and clinical trial activities. As of March 2026, there are 1.6 billion shares outstanding. The company funds its operations through equity offerings and convertible debt, which provides necessary capital but results in the issuance of additional shares and potential dilution of existing shareholder ownership.

4. Key risks for investors

• Dilution: Because the company relies on selling stock to fund ongoing operations, the total share count has increased over time. Investors should monitor future filings for additional equity offerings, which are likely as the company prepares for a potential commercial launch.
• Regulatory Hurdles: The company is currently navigating the final stages of the regulatory process. There is a risk that health authorities, such as the FDA or MHRA, may require additional studies or data, which could extend the timeline for approval and increase the need for further capital.
• Market Competition: The oncology sector is highly competitive, featuring large pharmaceutical companies with significant marketing and distribution resources. Even if approved, NWBO will need to compete against established standard-of-care treatments to capture market share.

5. Future outlook

The company is transitioning its focus from clinical testing to manufacturing readiness. The acquisition of Flaskworks is intended to automate the production of their therapies. Moving from manual processes to an automated system is a strategic step to lower costs and scale production for a potential commercial launch. Success in the coming years is tied to the outcome of the U.K. regulatory review and the company's ability to secure the necessary funding or strategic partnerships to bring their products to market.

Bottom line: This is a high-risk, high-reward investment. You are evaluating a company that is currently pre-revenue, meaning your investment thesis rests on the potential for their clinical data to translate into regulatory approval and a successful commercial product. Before investing, consider whether your portfolio can withstand the volatility typical of clinical-stage biotech companies.